BR112018016398A2 - métodos para o uso de 5'-adenosina difosfato ribose (adpr) - Google Patents
métodos para o uso de 5'-adenosina difosfato ribose (adpr)Info
- Publication number
- BR112018016398A2 BR112018016398A2 BR112018016398A BR112018016398A BR112018016398A2 BR 112018016398 A2 BR112018016398 A2 BR 112018016398A2 BR 112018016398 A BR112018016398 A BR 112018016398A BR 112018016398 A BR112018016398 A BR 112018016398A BR 112018016398 A2 BR112018016398 A2 BR 112018016398A2
- Authority
- BR
- Brazil
- Prior art keywords
- adpr
- methods
- adenosine diphosphate
- diphosphate ribose
- diseases
- Prior art date
Links
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 title abstract 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 title abstract 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 241000701161 unidentified adenovirus Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
a presente invenção se refere a métodos para o uso de 5'-adenosina difosfato ribose (adpr) e suas composições para tratar, controlar ou prevenir doenças ou condições relacionadas ao adenovírus, distúrbios oculares, câncer ou doenças ou condições provocadas por infecção, inflamação ou lesões físicas, químicas, térmicas ou de radiação.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662296665P | 2016-02-18 | 2016-02-18 | |
| US201662428721P | 2016-12-01 | 2016-12-01 | |
| PCT/US2017/018253 WO2017143113A1 (en) | 2016-02-18 | 2017-02-17 | Methods for the use of 5'-adenosine diphosphate ribose (adpr) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018016398A2 true BR112018016398A2 (pt) | 2018-12-18 |
Family
ID=58191671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018016398A BR112018016398A2 (pt) | 2016-02-18 | 2017-02-17 | métodos para o uso de 5'-adenosina difosfato ribose (adpr) |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11110112B2 (pt) |
| EP (2) | EP3978003A1 (pt) |
| JP (3) | JP6946353B2 (pt) |
| KR (2) | KR102622656B1 (pt) |
| CN (2) | CN108601793B (pt) |
| AU (2) | AU2017219878B2 (pt) |
| BR (1) | BR112018016398A2 (pt) |
| CA (1) | CA3014071A1 (pt) |
| DK (1) | DK3416654T3 (pt) |
| ES (1) | ES2900524T3 (pt) |
| HR (1) | HRP20211942T1 (pt) |
| HU (1) | HUE057052T2 (pt) |
| IL (2) | IL261095B (pt) |
| LT (1) | LT3416654T (pt) |
| PL (1) | PL3416654T3 (pt) |
| PT (1) | PT3416654T (pt) |
| WO (1) | WO2017143113A1 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3416654T (pt) | 2016-02-18 | 2021-12-22 | Invirsa Inc | Métodos para a utilização de 5¿-adenosina difosfato ribose (adpr) |
| ES2949441T3 (es) | 2018-03-27 | 2023-09-28 | Invirsa Inc | Métodos para el uso de 5'-adenosina difosfato ribosa (ADPR) |
| KR20230036274A (ko) * | 2021-09-07 | 2023-03-14 | 정근영 | 방사선 및/또는 항암 치료 보조 요법으로 아데노신 디포스페이트 리보오스의 활용 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0618214A1 (en) | 1993-04-01 | 1994-10-05 | Merrell Dow Pharmaceuticals Inc. | Unsaturated phosphonate derivatives of purines and pyrimidines |
| JPH07247210A (ja) | 1994-03-09 | 1995-09-26 | Sunstar Inc | 口腔用組成物 |
| US6339073B1 (en) * | 1997-09-11 | 2002-01-15 | Oxigene, Inc. | Uses of nicotinamide adenine dinucleotide and its derivatives for treatment of malignant and infectious diseases |
| MXPA01008547A (es) | 1999-02-26 | 2003-06-06 | Inspire Pharmaceuticals Inc | Metodo para promover la hidratacion de mucosas con ciertos difosfatos de uridina, adenina y citidina, y analogos de estos. |
| JP2003502033A (ja) | 1999-06-16 | 2003-01-21 | アイコス コーポレイション | ヒトポリ（ａｄｐ−リボース）ポリアミラーゼ２材料および方法 |
| US6528042B1 (en) | 1999-10-08 | 2003-03-04 | Galileo Laboratories, Inc. | Compositions of flavonoids for use as cytoprotectants and methods of making and using them |
| US7115585B2 (en) | 2000-08-21 | 2006-10-03 | Inspire Pharmaceuticals, Inc. | Compositions for treating epithelial and retinal tissue diseases |
| WO2003011885A1 (en) | 2001-07-25 | 2003-02-13 | Celltech R & D Limited | Non-natural carbon-linked nucleotides and dinucleotides |
| US20030236217A1 (en) | 2002-05-21 | 2003-12-25 | Shalwitz Robert A. | Treatment of mucositis |
| US20070212395A1 (en) | 2006-03-08 | 2007-09-13 | Allergan, Inc. | Ocular therapy using sirtuin-activating agents |
| US20050276762A1 (en) | 2004-06-15 | 2005-12-15 | Tapas Das | Topical compositions containing 5'-adenosine-diphosphate ribose |
| EP1928440A2 (en) | 2005-05-25 | 2008-06-11 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
| EP1948215B1 (en) | 2005-11-14 | 2012-01-11 | Centre National De La Recherche Scientifique (Cnrs) | MacroH2A non-histone domain as inhibitor of PARP-1 activity and uses thereof |
| WO2008154129A1 (en) | 2007-06-08 | 2008-12-18 | Bausch & Lomb Incorporated | Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye |
| US20110217262A1 (en) | 2010-03-05 | 2011-09-08 | Kornfield Julia A | Treatment of Ocular Surface Disorders by Increasing Conjunctival Vascular Permeability |
| JP2013526514A (ja) | 2010-05-10 | 2013-06-24 | ラディカル・セラピューティックス・インコーポレイテッド | リポ酸およびニトロキシド誘導体およびその使用 |
| AU2012253335B2 (en) | 2011-05-12 | 2016-08-04 | Takeda Pharmaceutical Company Limited | Stable povidone-iodine compositions with steroids or non-steroidal anti-inflammatories |
| US20160287622A1 (en) | 2013-11-18 | 2016-10-06 | Massachusetts Institute Of Technology | Compositions and methods for treating immune and viral disorders and modulating protein-rna interaction |
| PT3416654T (pt) | 2016-02-18 | 2021-12-22 | Invirsa Inc | Métodos para a utilização de 5¿-adenosina difosfato ribose (adpr) |
| ES2949441T3 (es) | 2018-03-27 | 2023-09-28 | Invirsa Inc | Métodos para el uso de 5'-adenosina difosfato ribosa (ADPR) |
-
2017
- 2017-02-17 PT PT177081049T patent/PT3416654T/pt unknown
- 2017-02-17 CN CN201780011126.0A patent/CN108601793B/zh active Active
- 2017-02-17 US US15/999,269 patent/US11110112B2/en active Active
- 2017-02-17 LT LTEPPCT/US2017/018253T patent/LT3416654T/lt unknown
- 2017-02-17 PL PL17708104T patent/PL3416654T3/pl unknown
- 2017-02-17 CN CN202311353882.5A patent/CN117482102A/zh active Pending
- 2017-02-17 AU AU2017219878A patent/AU2017219878B2/en active Active
- 2017-02-17 CA CA3014071A patent/CA3014071A1/en active Pending
- 2017-02-17 BR BR112018016398A patent/BR112018016398A2/pt not_active Application Discontinuation
- 2017-02-17 EP EP21198288.9A patent/EP3978003A1/en active Pending
- 2017-02-17 EP EP17708104.9A patent/EP3416654B1/en active Active
- 2017-02-17 DK DK17708104.9T patent/DK3416654T3/da active
- 2017-02-17 JP JP2018563379A patent/JP6946353B2/ja active Active
- 2017-02-17 ES ES17708104T patent/ES2900524T3/es active Active
- 2017-02-17 KR KR1020187022959A patent/KR102622656B1/ko active IP Right Grant
- 2017-02-17 HU HUE17708104A patent/HUE057052T2/hu unknown
- 2017-02-17 WO PCT/US2017/018253 patent/WO2017143113A1/en active Application Filing
- 2017-02-17 HR HRP20211942TT patent/HRP20211942T1/hr unknown
- 2017-02-17 KR KR1020237034890A patent/KR20230148389A/ko active Application Filing
-
2018
- 2018-08-10 IL IL261095A patent/IL261095B/en unknown
-
2021
- 2021-08-03 US US17/392,578 patent/US11857561B2/en active Active
- 2021-09-15 JP JP2021149881A patent/JP7222042B2/ja active Active
-
2022
- 2022-03-21 IL IL291574A patent/IL291574A/en unknown
-
2023
- 2023-02-02 JP JP2023014497A patent/JP2023055858A/ja active Pending
- 2023-03-17 AU AU2023201678A patent/AU2023201678A1/en active Pending
- 2023-11-07 US US18/503,967 patent/US20240091249A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124055T1 (el) | Ετεροκυκλικες ενωσεις ως ανοσοδιαμορφωτες | |
| PH12019501443A1 (en) | Benzooxazole derivatives as immunomodulators | |
| MX2021005087A (es) | Compuestos de formula i para usarse en el tratamiento de infecciones por virus arenaviridae y coronaviridae. | |
| BR112018000542A2 (pt) | composições de irna de transtirretina (ttr) e métodos de uso das mesmas para o tratamento ou prevenção de doenças associadas à ttr | |
| BR112018074185A2 (pt) | 3-oxo-2,6-difenil-2,3-di-hidropiridazina-4-carboxamidas | |
| BR112019002576A2 (pt) | composto, medicamento¸ métodos para inibição de gcn2 em um mamífero e para a profilaxia ou tratamento de câncer em um mamífero, e, uso do composto ou um sal do mesmo | |
| BR112015023753A2 (pt) | composições, formulações e métodos para o tratamento de doenças oculares | |
| CL2019000935A1 (es) | Composición farmacéutica, métodos para tratamiento y usos de la misma. | |
| BR112017009497A2 (pt) | polinucleotídeos de aadc para o tratamento da doença de parkinson | |
| BR112016025048A2 (pt) | compostos e composições como agonistas do receptor tipo toll7 | |
| PH12016501966A1 (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| BR112019016497A2 (pt) | 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de câncer. | |
| BR112019002646A2 (pt) | composições de poxvírus quimérico e usos das mesmas | |
| BR112018014794A2 (pt) | pirimidinas substituídas com arila para uso em infecção pelo vírus influenza | |
| BR112021022951A2 (pt) | Composições e métodos para o tratamento de doenças mediadas por atpase | |
| BR112017004153A2 (pt) | métodos para tratamento de infecções por protozoários | |
| BR112018074483A2 (pt) | proteínas f do rsv pré-fusão estabilizadas | |
| AU2016380190A8 (en) | Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof | |
| GT201600250A (es) | Compuestos de 1, 3, 4- tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| BR112017022158A2 (pt) | compostos, composições farmacêuticas e uso de um composto | |
| BR112017022653A2 (pt) | ?métodos para o tratamento ou para a prevenção de uma doença, da artrite reumatoide, da prostatite e da bph? | |
| BR112019006802A2 (pt) | compostos e métodos para diagnóstico e tratamento de infecções virais | |
| MX2024007360A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. | |
| BR112017027277A2 (pt) | ?método para o tratamento ou prevenção de uma doença e métodos para matar uma célula? | |
| BR112018016398A2 (pt) | métodos para o uso de 5'-adenosina difosfato ribose (adpr) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |